阿比多尔抗病毒的研究现状  

Current status of arbidol in antiviral research

作　　者：吴小街[1] 颜恒毅[1] 赵立[1] WU Xiao-jie;YAN Heng-yi;ZHAO Li(Department of Pulmonary and Critical Care Medicine,Shengjing Hospital of China Medical University,Shenyang 110004,Liaoning Province,China)

机构地区：[1]中国医科大学附属盛京医院呼吸与危重症医学科,辽宁沈阳110004

出　　处：《中国临床药理学杂志》2020年第12期1743-1745,1751,共4页The Chinese Journal of Clinical Pharmacology

基　　金：重大新药创制科技重大专项基金资助项目(2020ZX09201-011)。

摘　　要：阿比多尔是一种非核苷类广谱抗病毒药物,主要通过抑制膜融合及免疫调节机制发挥抗病毒作用,该药在中国被批准用于治疗甲、乙型流感病毒引起的上呼吸道感染。体外实验证实阿比多尔对其他多种呼吸道病毒有抑制作用,包括严重急性呼吸综合征冠状病毒(SARS-CoV)和新型冠状病毒(SARS-CoV-2),但尚缺乏临床试验证据。本文着重介绍阿比多尔的药理学特点、抗病毒机制,对阿比多尔在治疗新型冠状病毒肺炎(COVID-19)中的作用进行探讨,旨在为阿比多尔在抗病毒中的合理使用提供理论依据。Arbidol,a non-nucleoside broad-spectrum antiviral molecule,is licensed in China for the use against influenza A and B viruses.The main antiviral mechanism of arbidol is considered to block virus fusion with cytomembrane and immunomodulate cytokines.Arbidol also exhibits inhibitory activity in a variety of respiratory viruses in vitro,including severe acute respiratory syndrome coronavirus(SARS-CoV)and severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),but clinical trial evidence is lacking.This review mainly focuses on the pharmacological characteristics and antiviral mechanism of arbidol and explores its potential role in the treatment of coronavirus disease 2019,which may help to provide a theoretical basis for the antiviral using of arbidol.

关 键 词：阿比多尔 新型冠状病毒 新型冠状病毒肺炎 

分 类 号：R97[医药卫生—药品]